TherapeuticsMD (TXMD) Income from Continuing Operations (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Income from Continuing Operations came in at $164000.0 in Q2 2026, down 69.91% on a YoY basis from $545000.0 in Q2 2025, and up 59.22% quarter-over-quarter from $103000.0 in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported Income from Continuing Operations for 17 consecutive years, with $164000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations fell 69.91% year-over-year to $164000.0; the trailing twelve-month figure through Jun 2026 stood at -$263000.0 (up 54.26% YoY), and the FY2025 full-year result was -$653000.0, up 71.76% from the prior year.
- Income from Continuing Operations improved to $164000.0 in Q2 2026 per TXMD's latest filing, from $103000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $48.5 million in Q4 2022 and bottomed at -$17.9 million in Q1 2022.
- Historically, Income from Continuing Operations has averaged -$536944.4 across 5 years, with a median of -$722500.0 in 2024.
- The widest YoY moves for Income from Continuing Operations: up 151.9% in 2025, down 798.8% in 2025.
- Over 5 years, Income from Continuing Operations stood at $48.5 million in 2022, then slumped by 103.27% to -$1.6 million in 2023, then jumped by 105.24% to $83000.0 in 2024, then plunged by 798.8% to -$580000.0 in 2025, then soared by 128.28% to $164000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $164000.0, $103000.0, and -$580000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -246.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 3.32 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 2.16 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -644.37 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 237.01 Mn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 164,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 164,000.00 |
| Mar 31, 2026 | 103,000.00 |
| Dec 31, 2025 | -580,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 545,000.00 |
| Mar 31, 2025 | -636,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | -567,000.00 |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -809,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | -1.43 Mn |
| Jun 30, 2023 | -2.41 Mn |
| Mar 31, 2023 | -2.31 Mn |
| Dec 31, 2022 | 48.45 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | -15.47 Mn |
| Mar 31, 2022 | -17.88 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |